Group 1: Strategic Emerging Industries Development - The government work report emphasizes the promotion of integrated cluster development in strategic emerging industries, highlighting the formation of substantial industrial clusters in the Sci-Tech Innovation Board [1] - The Sci-Tech Innovation Board has 113 listed companies in the biopharmaceutical sector, focusing on treatments for cancer, AIDS, and hepatitis B, making it a major listing venue globally outside the US and Hong Kong [1] - In the integrated circuit sector, there are 119 companies, representing a significant portion of A-share listed companies, with a complete industrial chain from chip design to packaging and testing [1] Group 2: Biopharmaceutical Sector Innovations - The National Medical Products Administration approved 11 new drugs, with five from Sci-Tech Innovation Board companies, indicating a strong performance in drug innovation [2] - Eight new drugs have been approved for Sci-Tech Innovation Board innovative drug companies this year, with a total of 33 globally new class 1 drugs launched since 2018, accounting for 14% of domestic approvals [2] - The medical device sector has seen increased domestic production rates for high-end imaging equipment, with companies establishing resilient supply chains [2] Group 3: Integrated Circuit Industry Growth - The integrated circuit sector reported a net profit of 4.479 billion yuan in Q1, a 73% year-on-year increase, driven by domestic substitution and demand recovery [4] - Companies in the chip design and semiconductor equipment sectors have shown significant revenue and profit growth, with some companies like Hengxuan Technology achieving a 590.22% increase in net profit [4][5] - The production capacity and order status of wafer manufacturing companies remain strong, with major players like SMIC and Huahong maintaining high utilization rates [5] Group 4: Strategic Expansion and Internationalization - Companies in the Sci-Tech Innovation Board are exploring mergers and acquisitions to achieve external growth, with recent announcements of mergers such as Haiguang Information and Zhongke Shuguang [6] - The internationalization of biopharmaceutical companies is accelerating, with 11 companies granting overseas rights to their innovative drugs, marking a significant step towards global market entry [7] - The collaboration between domestic companies and global research institutions is increasing, with over 55 top research institutions engaged in partnerships, facilitating the global transformation of innovative results [7]
聚链成势 科创板“硬科技”集群擎起自立自强 “大旗”
Zheng Quan Shi Bao Wang·2025-06-10 09:41